

THE #1 DISPENSED NAIL FUNGUS TREATMENT IN CANADA*


Indicated for the topical treatment of mild to moderate onychomycosis (tinea unguium) of toenails without lunula involvement due to *Trichophyton rubrum* and *Trichophyton mentagrophytes* in immunocompetent adult patients.



Demonstrated results in treating nail fungus topically†

Complete cure‡
(primary endpoint)

Almost complete cure§
(secondary endpoint)



Representative clinical photographs of two patients with moderate onychomycosis.

Demonstrated low incidence of adverse reactions†

- Total number of patients who reported a treatment-emergent adverse reaction was 6.1% JUBLIA™, 3.5% vehicle
- The only treatment-emergent adverse reactions reported by ≥1% of patients were application site dermatitis (2.0% JUBLIA™, 0.2% vehicle) and application site vesicles (1.4% JUBLIA™, 0.0% vehicle)

Patient counselling tips

- Use JUBLIA™ for the full treatment period recommended by the doctor
- Stopping JUBLIA™ too soon may cause the infection to restart
- Treatment may take several months to work so don't expect the infection to clear up quickly
- Apply one drop to affected toenail(s) and two drops to affected big toenail(s) once daily, preferably at bedtime
- Fungal infections like onychomycosis can be difficult to clear up. Even when treated it can take 12 to 18 months for the infected nail to grow out
- Avoid nail polish, cosmetic nail products, or pedicures from a non-healthcare professional while using JUBLIA™
- It is important to refill your prescription on time, so you don't miss any applications

CLINICAL USE:

Safety and efficacy in patients under 18 or over 75 have not been studied. Greater sensitivity of some older individuals (≥65) cannot be ruled out.

CONTRAINDICATIONS:

- Hypersensitivity to efinaconazole or any excipients of JUBLIA™ or container component

RELEVANT WARNINGS AND PRECAUTIONS:

- Patients with a history or clinical signs of immunosuppression, HIV infection, uncontrolled diabetes, other toenail infection except *Candida*, toenail infection to the matrix, only lateral toenail disease, severe plantar tinea pedis
- Concomitant use of other antifungal therapy and daily use of JUBLIA™ for more than 48 weeks
- For topical use only, and only on toenails and immediately adjacent skin
- Flammable – keep away from heat or flame
- Sensitivity reaction or severe irritation
- Pregnant and nursing women

FOR MORE INFORMATION:

Please see Product Monograph on the Health Canada website (<http://webprod5.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp>) for important information on adverse reactions, drug interactions and dosing. Product Monograph is also available by calling 1-800-361-4261.

* Source: IMS Brogan CompuScript Audit, January 2017.

† Two identical 48-week, randomized, double-blind, vehicle-controlled trials with 4-week post follow-up in 1,601 patients (1,198 JUBLIA™, 403 vehicle) with 20-50% clinical involvement of area of target great toenail, without dermatophytomas or lunula (matrix) involvement. Patients not excluded for concomitant *Candida* infection.

‡ Defined as 0% clinical involvement of target toenail plus mycologic cure.

§ Defined as ≤5% clinical involvement of target toenail plus mycologic cure.

REFERENCES: 1. JUBLIA™ Product Monograph, October 2013. 2. Elewski BE, Rich P, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. *J Am Acad Dermatol* 2013;Vol 68, No 4:600-608.

VALEANT
Valeant Canada
valeantcanada.com


JUBLIA™ is a trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.

Valeant Canada LP, 2150 St-Elzéar Blvd. West
Laval, Quebec H7L 4A8

© 2017 Valeant Canada LP. All rights reserved.



ONCE-DAILY



JUBLIA™

(efinaconazole) Topical Solution, 10% w/w

Demonstrated efficacy in a topical.